PT1105409E - Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue - Google Patents

Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue

Info

Publication number
PT1105409E
PT1105409E PT00936023T PT00936023T PT1105409E PT 1105409 E PT1105409 E PT 1105409E PT 00936023 T PT00936023 T PT 00936023T PT 00936023 T PT00936023 T PT 00936023T PT 1105409 E PT1105409 E PT 1105409E
Authority
PT
Portugal
Prior art keywords
peptide
terminus
amino acid
protection
activity
Prior art date
Application number
PT00936023T
Other languages
English (en)
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Thibaudeau Karen
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of PT1105409E publication Critical patent/PT1105409E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT00936023T 1999-05-17 2000-05-17 Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue PT1105409E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
US15978399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
PT1105409E true PT1105409E (pt) 2006-07-31

Family

ID=27384581

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00936023T PT1105409E (pt) 1999-05-17 2000-05-17 Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue

Country Status (11)

Country Link
EP (5) EP1105409B1 (pt)
JP (6) JP4217004B2 (pt)
AT (1) ATE318835T1 (pt)
AU (1) AU765753B2 (pt)
CA (4) CA2505617A1 (pt)
DE (1) DE60026300T2 (pt)
DK (1) DK1105409T3 (pt)
ES (1) ES2257298T3 (pt)
PT (1) PT1105409E (pt)
SI (1) SI1105409T1 (pt)
WO (1) WO2000069900A2 (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
EP1355941A2 (en) * 2001-02-02 2003-10-29 ConjuChem, Inc. Long lasting growth hormone releasing factor derivatives
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
CA2444530A1 (en) * 2001-04-18 2002-10-24 The Open University Polypeptides, derivatives and uses thereof
EP1401862A4 (en) * 2001-05-17 2004-12-15 Ceremedix Inc PEPTIDE COMPOUNDS AGAINST OXYGENIC SUBSTANCES AND FREE RADICALS
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
WO2002097444A2 (en) 2001-05-31 2002-12-05 Arete Associates Misfolded protein sensor method
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
US7544653B2 (en) * 2001-10-18 2009-06-09 Zlatko Ademovic Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone
US6822073B2 (en) * 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
EP1489093A4 (en) * 2002-03-19 2005-07-20 Oncorex Inc PEPTIDES, MEDICAL COMPOSITIONS CONTAINING PEPTIDES, AND MEDICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
JP2004008027A (ja) * 2002-06-04 2004-01-15 Japan Science & Technology Corp ｃＡＭＰの産生活性を有する新規ペプチド
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
EP1530588A2 (en) * 2002-07-31 2005-05-18 Conjuchem, Inc. Long lasting natriuretic peptide derivatives
CA2500248C (en) * 2002-09-24 2013-03-19 Frontier Biotechnologies Co., Ltd. Peptide derivative fusion inhibitors of hiv infection
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
CA2504287A1 (en) 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
WO2004062693A1 (ja) * 2003-01-10 2004-07-29 Niigata Tlo Corporation 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法
AU2003210714A1 (en) * 2003-01-29 2004-08-30 Advanced Research And Technology Institute, Inc. Immunoregulating compounds and an associated method
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2004097423A1 (en) * 2003-04-25 2004-11-11 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
AU2005211776B2 (en) * 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005090399A1 (ja) * 2004-03-24 2005-09-29 Gifu International Institute Of Biotechnology 各種細胞の増殖・分化を認識する抗体、その抗体を用いた増殖・分化の評価方法
US7838245B2 (en) * 2004-04-20 2010-11-23 Sphingotec Gmbh Use of precursors of tachykinins and/or their fragments in medical diagnostic
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
ES2431288T3 (es) * 2004-05-13 2013-11-25 B.R.A.H.M.S Gmbh Uso de precursores de encefalinas y/o sus fragmentos en diagnosis médica
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US7704955B2 (en) 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
JP4720175B2 (ja) * 2004-12-15 2011-07-13 富士ゼロックス株式会社 マレイミジル基含有材料およびその製造方法
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
WO2006088823A2 (en) 2005-02-15 2006-08-24 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20080292627A1 (en) * 2005-05-05 2008-11-27 The Board Of Trustees Of The University Of Illinois Compositions and Methods for Treating Mood and Anxiety Disorders
KR20080072639A (ko) * 2005-10-27 2008-08-06 주식회사 펩트론 생리활성 기질-혈액 단백질 복합체 및 이를 이용하는생리활성 기질의 안정화 방법
CA2647835A1 (en) 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
CA2683288A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
WO2009033707A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2698912A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009040030A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100184680A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
JP5588354B2 (ja) * 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
WO2009142727A2 (en) * 2008-05-19 2009-11-26 Vasogenix Pharmaceuticals, Inc. Sequence modified calcitonin gene related peptides (cgrp)
US20120003695A1 (en) 2009-02-25 2012-01-05 Davidson Robert C Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
MX2012001193A (es) * 2009-07-29 2012-03-14 Daiichi Sankyo Co Ltd Compuesto peptidico similar a motilina con capacidad de absorcion transmucosa impartida al mismo.
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
MX2012001141A (es) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Composicion de insulina de accion prolongada.
CA2779161A1 (en) 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
MX2012009802A (es) 2010-02-24 2012-09-12 Merck Sharp & Dohme Metodo para incrementar la ocupacion del sitio de n-glucosilacion en glucoproteinas terapeuticas producidas en pichia pastoris.
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
CN103282510A (zh) 2010-08-13 2013-09-04 爱勒让治疗公司 拟肽大环化合物
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
EP2822572B1 (en) 2012-02-15 2020-06-10 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP2013179884A (ja) * 2012-03-01 2013-09-12 Mitsubishi Rayon Co Ltd メラニンカスケードに関与する成分を評価するための核酸マイクロアレイ及びメラニンカスケードに関与する成分の評価方法
JP6195911B2 (ja) 2012-05-17 2017-09-13 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 向上した薬物送達のための担体
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
WO2015001015A1 (en) * 2013-07-04 2015-01-08 Universitat De Barcelona Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs
AU2015207776B2 (en) * 2014-01-15 2017-06-15 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated peptides for lowering blood glucose
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN107530398B (zh) * 2015-02-22 2021-10-29 欧姆尼克斯医疗有限公司 抗微生物肽
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
JP2019513711A (ja) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP6965362B2 (ja) 2017-03-01 2021-11-10 チェンドゥ フイタイ バイオメディスン カンパニー リミテッドChengdu Huitai Biomedicine Co., Ltd. ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2018221745A1 (ja) * 2017-06-02 2018-12-06 株式会社Ｌｓｉメディエンス 生体試料中からの標的タンパク質の抽出方法および標的タンパク質の分析方法
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
WO2019106193A1 (en) 2017-12-01 2019-06-06 University Of Copenhagen Peptide hormone with one or more o-glycans
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2019197313A1 (en) 2018-04-09 2019-10-17 Svar Life Science Ab Glucagon Assay
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
BE795238A (fr) * 1972-02-09 1973-08-09 Schering Ag Derives d'insuline reticules de maniere intramoleculaire, leur procede de preparation et leur utilisation
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DD252539A1 (de) * 1986-09-17 1987-12-23 Berlin Chemie Veb Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
AU4399093A (en) 1992-06-12 1994-01-04 Des-Tyr Dynorphin Partnership Des-tyr dynorphin analogues
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
JPH10511077A (ja) 1994-08-26 1998-10-27 ナンシー、 エム． リー、 Ｎ末端基で切断されたダイノルフィン類似体を用いた鎮痛方法
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
WO1998035033A1 (en) * 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
EP1007561B1 (en) * 1997-11-07 2002-04-17 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1950224A3 (en) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2291066A1 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Local delivery of long lasting therapeutic agents

Also Published As

Publication number Publication date
DE60026300T2 (de) 2006-11-16
JP2005263807A (ja) 2005-09-29
DK1105409T3 (da) 2006-07-03
JP2005239736A (ja) 2005-09-08
EP1591453A1 (en) 2005-11-02
WO2000069900A9 (en) 2002-07-04
EP1105409B1 (en) 2006-03-01
JP2003508350A (ja) 2003-03-04
JP4217004B2 (ja) 2009-01-28
ATE318835T1 (de) 2006-03-15
CA2499211A1 (en) 2000-11-23
AU765753B2 (en) 2003-09-25
WO2000069900A3 (en) 2001-02-15
ES2257298T3 (es) 2006-08-01
AU5139300A (en) 2000-12-05
EP1623994A2 (en) 2006-02-08
JP4219339B2 (ja) 2009-02-04
DE60026300D1 (de) 2006-04-27
WO2000069900A2 (en) 2000-11-23
CA2373680C (en) 2008-07-29
SI1105409T1 (sl) 2006-06-30
JP4221392B2 (ja) 2009-02-12
JP2008150384A (ja) 2008-07-03
JP2009079048A (ja) 2009-04-16
EP1105409A2 (en) 2001-06-13
JP2010168384A (ja) 2010-08-05
EP1598365A1 (en) 2005-11-23
EP1623994A3 (en) 2008-07-16
CA2373680A1 (en) 2000-11-23
CA2505617A1 (en) 2000-11-23
EP2100901A1 (en) 2009-09-16
CA2623458A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
PT1105409E (pt) Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
PL312989A1 (en) Therapeutic derivatives of peptides
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
SE0002202D0 (sv) New peptides
AU6898201A (en) Rgd (arg-gly-asp) coupled to (neuro)peptides
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
CA2373252A1 (en) Long lasting anti-angiogenic peptides
EP0759772A4 (en) TRI-, TETRA-, PENTA- AND POLYPEPTIDES AND THEIR THERAPEUTIC USE AS AN ANTIDEPRESSANT AGENT
AUPO089396A0 (en) Neuroactive peptide
TW200602353A (en) Modified secretin and method of synthesizing thereof
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
WO2000020572A3 (de) Gewebebindende peptide, ihre identifizierung, herstellung und verwendung